| Citation: |
ZHANG Xue, LI Xi, LEI Yi, et al. Ocular immune-related adverse event associated with PD-1: a case report[J]. Chin J Clin Med, 2022, 29(4): 708-711. DOI: 10.12025/j.issn.1008-6358.2022.20220436
|
| [1] |
DE RE V, CAGGIARI L, REPETTO O, et al. Classical Hodgkin's lymphoma in the era of immune checkpoint inhibition[J]. J Clin Med, 2019, 8(10): 1596. DOI: 10.3390/jcm8101596
|
| [2] |
XU-MONETTE Z Y, ZHOU J F, YOUNG K H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas[J]. Blood, 2018, 131(1): 68-83. DOI: 10.1182/blood-2017-07-740993
|
| [3] |
TUMEH P C, HARVIEW C L, YEARLEY J H, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528): 568-571. DOI: 10.1038/nature13954
|
| [4] |
MICHOT J M, BIGENWALD C, CHAMPIAT S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review[J]. Eur J Cancer, 2016, 54: 139-148. DOI: 10.1016/j.ejca.2015.11.016
|
| [5] |
徐欣植, 杨骥. 肿瘤靶向药及免疫检查点抑制剂相关皮肤病及诊治进展[J]. 中国临床医学, 2021, 28(6): 943-947. http://www.c-jcm.com/zglcyx/ch/reader/view_abstract.aspx?file_no=20210559&flag=1
XU X Z, YANG J. Advances in diagnosis and treatment of cutaneous adverse events associated with tumor targeted drugs and immune checkpoint inhibitos[J]. Chinese Journal of Clinical Medicine, 2021, 28(6): 943-947. http://www.c-jcm.com/zglcyx/ch/reader/view_abstract.aspx?file_no=20210559&flag=1
|
| [6] |
EIGENTLER T K, HASSEL J C, BERKING C, et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45: 7-18. DOI: 10.1016/j.ctrv.2016.02.003
|
| [7] |
ZIMMER L, GOLDINGER S M, HOFMANN L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60: 210-225. DOI: 10.1016/j.ejca.2016.02.024
|
| [8] |
ABDEL-RAHMAN O, OWEIRA H, PETRAUSCH U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review[J]. Expert Rev Anticancer Ther, 2017, 17(4): 387-394. DOI: 10.1080/14737140.2017.1296765
|
| [9] |
ANTOUN J, TITAH C, COCHEREAU I. Ocular and orbital side-effects of checkpoint inhibitors: a review article[J]. Curr Opin Oncol, 2016, 28(4): 288-294. DOI: 10.1097/CCO.0000000000000296
|
| [10] |
BITTON K, MICHOT J M, BARREAU E, et al. Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy[J]. Am J Ophthalmol, 2019, 202: 109-117. DOI: 10.1016/j.ajo.2019.02.012
|
| [11] |
DALVIN L A, SHIELDS C L, ORLOFF M, et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects[J]. Retina, 2018, 38(6): 1063-1078. DOI: 10.1097/IAE.0000000000002181
|
| [12] |
BRAHMER J R, TYKODI S S, CHOW L Q, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26): 2455-2465. DOI: 10.1056/NEJMoa1200694
|
| [13] |
HELLMAN J B, TRAYNIS I, LIN L K. Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia[J]. Orbit, 2019, 38(3): 244-247. DOI: 10.1080/01676830.2018.1490439
|
| [14] |
NASR F, EL RASSY E, MAALOUF G, et al. Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab[J]. Eur J Cancer, 2018, 91: 171-173. DOI: 10.1016/j.ejca.2017.11.026
|
| [15] |
OKIYAMA N, TANAKA R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors[J]. Allergol Int, 2022, 71(2): 169-178. DOI: 10.1016/j.alit.2022.01.001
|
| [16] |
MATAS-GARCÍA A, MILISENDA J C, SELVA-O'CALLAGHAN A, et al. Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern[J]. Autoimmun Rev, 2020, 19(2): 102455. DOI: 10.1016/j.autrev.2019.102455
|
| [17] |
MARTINS F, SOFIYA L, SYKIOTIS G P, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance[J]. Nat Rev Clin Oncol, 2019, 16(9): 563-580. DOI: 10.1038/s41571-019-0218-0
|
| [18] |
MARINO M, IONNI I, LANZOLLA G, et al. Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis[J]. J Endocrinol Invest, 2020, 43(4): 401-411. DOI: 10.1007/s40618-019-01141-3
|
| [19] |
SUN B, SONG L, WANG X, et al. Lymphoma and inflammation in the orbit: diagnostic performance with diffusion-weighted imaging and dynamic contrast-enhanced MRI[J]. J Magn Reson Imaging, 2017, 45(5): 1438-1445. DOI: 10.1002/jmri.25480
|
DownLoad: